ENXTPA:SANPharmaceuticals
Sanofi (ENXTPA:SAN) Valuation Check After New Dupixent Phase 4 Eosinophilic Esophagitis Results
Sanofi (ENXTPA:SAN) has drawn fresh attention after new REMODEL Phase 4 data for Dupixent in eosinophilic esophagitis, with clinically meaningful improvements in esophageal function and structure compared with placebo at week 24.
See our latest analysis for Sanofi.
Despite the fresh Dupixent data and other recent updates, such as the planned Dynavax acquisition, the Toronto AI expansion and a higher ordinary dividend, Sanofi’s short term share price return has been weak, with longer term...